Luvadaxistat is a potential first-in-class, investigational selective d-amino acid oxidase (DAAO) inhibitor for the treatment of negative and cognitive symptoms of schizophrenia. It targets glutamate, an abundant neurotransmitter in the brain. In schizophrenia, N-methyl D-aspartate (NMDA) receptor hypofunction on PV+ gamma-aminobutyric (GABA) interneurons results in disinhibition of cortical or hippocampal glutamate neurons projecting to the pyramidal neurons. The cortical disturbances account for the negative and cognitive symptoms of schizophrenia, while the downstream subcortical dopamine release manifests as the positive symptoms of the disorder.
Luvadaxistat is being developed by Neurocrine Biosciences and Takeda Pharmaceutical Company Limited as part of a strategic collaboration announced in June 2020.